Currently, the isoform-specific p110α inhibitor, BYL719, and the heat shock protein 90 inhibitor, AUY922, are being evaluated in a phase I trial with advanced stage GC patients that carry either a molecular alteration of PIK3CA, or ERBB2 amplification (NCT01613950) [92]. Here, PIK3CA is linked to gastric cancer.